| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.RES.0000088358.99466.04 |
| P698 | PubMed publication ID | 12881481 |
| P50 | author | Thomas Wieland | Q57326349 |
| P2093 | author name string | Rainer H Böger | |
| Süleyman Ergün | |||
| Anna Steenpass | |||
| Ralf Benndorf | |||
| P433 | issue | 5 | |
| P921 | main subject | endothelium | Q111140 |
| P304 | page(s) | 438-447 | |
| P577 | publication date | 2003-07-24 | |
| P1433 | published in | Circulation Research | Q2599020 |
| P1476 | title | Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells | |
| P478 | volume | 93 |
| Q46917813 | ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study |
| Q30434317 | ANG II type 2 receptor regulates smooth muscle growth and force generation in late fetal mouse development |
| Q36318813 | Activation of peroxisome proliferator-activated receptor α (PPARα) suppresses hypoxia-inducible factor-1α (HIF-1α) signaling in cancer cells |
| Q38826605 | Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials |
| Q39035051 | Angiotensin II evokes angiogenic signals within skeletal muscle through co-ordinated effects on skeletal myocytes and endothelial cells. |
| Q24338186 | Angiotensin II induces focal adhesion kinase/paxillin phosphorylation and cell migration in human umbilical vein endothelial cells |
| Q51825386 | Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice. |
| Q24294886 | Angiotensin II type 2 receptor-mediated gene expression profiling in human coronary artery endothelial cells |
| Q35314659 | Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation |
| Q89957914 | Angiotensin Receptor Blockers and the Risk of Cancer: Insights from Clinical Trials and Recent Drug Recalls |
| Q37395730 | Angiotensin receptors and β-catenin regulate brain endothelial integrity in malaria |
| Q40362859 | Antioxidant and nitric oxide-sparing actions of dihydropyridines and ACE inhibitors differ in human endothelial cells. |
| Q42518932 | Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with decreased risk for basal cell carcinoma. |
| Q38781876 | Catecholamines facilitate VEGF-dependent angiogenesis via β2-adrenoceptor-induced Epac1 and PKA activation |
| Q46499527 | Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart |
| Q92710285 | Counter-regulatory renin-angiotensin system in cardiovascular disease |
| Q39441029 | Cross-talk between endothelial and breast cancer cells regulates reciprocal expression of angiogenic factors in vitro |
| Q81097061 | Effects of angiotensin II on human endothelial cells survival signalling pathways and its angiogenic response |
| Q38783109 | Effects of angiotensin II receptor signaling during skin wound healing |
| Q38950662 | Elevated expression of placental growth factor is associated with airway-wall vascular remodelling and thickening in smokers with asthma |
| Q28506779 | Embryonic lethality in Dear gene-deficient mice: new player in angiogenesis |
| Q46953045 | Epidermal growth factor-like domain 7 protects endothelial cells from hyperoxia-induced cell death |
| Q34723357 | Genomic approach to identify factors that drive the formation of three-dimensional structures by EA.hy926 endothelial cells. |
| Q36354009 | Impact of AT2 receptor deficiency on postnatal cardiovascular development |
| Q36316657 | Integrated network model provides new insights into castration-resistant prostate cancer |
| Q36241932 | International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. |
| Q37243894 | Invited review: activity-induced angiogenesis |
| Q53290074 | LINE-1 retrotransposition events affect endothelial proliferation and migration |
| Q53850234 | Microvascular rarefaction and decreased angiogenesis in rats with fetal programming of hypertension associated with exposure to a low-protein diet in utero. |
| Q55041942 | Pharmacogenetic Aspects of the Interaction of AT1 Receptor Antagonists With ATP-Binding Cassette Transporter ABCG2. |
| Q27341905 | Preconditioning via angiotensin type 2 receptor activation improves therapeutic efficacy of bone marrow mononuclear cells for cardiac repair |
| Q52980831 | Regulation of colorectal cancer cell epithelial to mesenchymal transition by the renin angiotensin system. |
| Q30249043 | Renin-angiotensin system blockade for the risk of cancer and death |
| Q36938449 | Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by Akt-dependent mechanisms |
| Q85068072 | Skeletal muscle-endothelial cell cross talk through angiotensin II |
| Q35197237 | TRAIL, DR5 and caspase 3-dependent apoptosis in vessels of diseased human temporomandibular joint disc. An immunohistochemical study |
| Q53668736 | TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2. |
| Q37622575 | The angiotensin II type 2 receptor in cardiovascular disease |
| Q37622566 | The angiotensin II type 2 receptor in renal disease |
| Q48601476 | The effects of angiotensin peptides and angiotensin receptor antagonists on the cell growth and angiogenic activity of GH3 lactosomatotroph cells in vitro |
| Q37241365 | The natriuretic peptide/guanylyl cyclase--a system functions as a stress-responsive regulator of angiogenesis in mice |
| Q35591704 | The relevance of the Renin-Angiotensin system in the development of drugs to combat preeclampsia. |
| Q37218569 | The renin-angiotensin system and malignancy |
| Q39376362 | The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. |
| Q24311632 | Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis |
Search more.